Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
- DOI
- 10.1111/dom.14015
- Published
- 2020 Jul
- Container
- Diabetes, obesity & metabolism
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/dom.14015,
title = {Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.},
author = {Verma S and Sharma A and Zinman B and Ofstad AP and Fitchett D and Brueckmann M and Wanner C and Zwiener I and George JT and Inzucchi SE and Butler J and Mazer CD},
year = {2020},
journal = {Diabetes, obesity \& metabolism},
doi = {10.1111/dom.14015},
url = {https://doi.org/10.1111/dom.14015}
}RIS
TY - JOUR TI - Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. AU - Verma S AU - Sharma A AU - Zinman B AU - Ofstad AP AU - Fitchett D AU - Brueckmann M AU - Wanner C AU - Zwiener I AU - George JT AU - Inzucchi SE AU - Butler J AU - Mazer CD PY - 2020 JO - Diabetes, obesity & metabolism DO - 10.1111/dom.14015 UR - https://doi.org/10.1111/dom.14015 ER -
APA
S, V., A, S., B, Z., AP, O., D, F., M, B., C, W., I, Z., JT, G., SE, I., J, B., & CD, M. (2020). Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.14015
Source records
- pubmed · retrieved 2026-09-27T11:20:04.988Z